Privately-held Swiss dermatology company Galderma today announced today results from its new Phase IIIb RELAX clinical trial ...

Galderma, which listed in Zurich in March in one of the biggest initial public offerings of the year, specializes in skincare. It makes both consumer and pharmaceutical products and is the company ...

Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX ...

PARIS – L'Oréal is digging deeper into the dermatological products market, taking a 10 percent stake in Galderma, the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

The P 91 intermittent motion cartoner from Promatic has been in use at Galderma for over a year. In the French factory at Alby-sur-Chéran, the Swiss manufacturer of dermatological products declared ...

If both new products reach their $1 billion-plus sales potential it would have a transformative effect on Galderma, which recorded total group revenues of $3.26 billion in the first nine months of ...

Galderma generated $4 billion last year and ... to $4.1 billion in the first half compares with 9% growth in Consumer Products, notably L’Oréal Paris, NYX, Garnier and Maybelline, which reached ...

The regimen included Galderma products that contained well-known ingredients engineered to suit those with sensitive skin. In the morning and at night, patients used the hydrating Cetaphil Gentle ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and ...

Our offering at IMCAS brings our Integrated Dermatology Strategy to life, differentiates our products, and cements Galderma as the category leader in dermatology.” New data will include results ...

If both new products reach their $1 billion-plus sales potential it could have a transformative effect on Galderma, which recorded total group revenues of $2.2 billion in the first half of this year.